Stock comparison
BIOGEN INC. is 3.1x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($29.37 B vs $9.33 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
BIIB is larger
BIOGEN INC. is 3.1x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($29.37 B vs $9.33 B).
Market value leader
BIIB
BIOGEN INC. is 3.1x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($29.37 B vs $9.33 B).
Revenue leader
BIIB
HALO: $1.40B vs BIIB: $9.89B.
Profit leader
BIIB
HALO: $316.89M vs BIIB: $1.29B.
Margin leader
HALO
HALO: 22.7% vs BIIB: 13.1% net margin.
| Metric | HALO | BIIB |
|---|---|---|
| Market cap | $9.33 B | $29.37 B |
| US-listed rank | #998 | #476 |
| Revenue (latest FY) | $1.40B | $9.89B |
| Net income (latest FY) | $316.89M | $1.29B |
| Net margin | 22.7% | 13.1% |
| P/E (trailing FY) | 29.4x | 22.7x |
| SEC filings | 1,479 | 2,690 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
BIOGEN INC. is 3.1x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($29.37 B vs $9.33 B).
In their latest fiscal years, HALOZYME THERAPEUTICS, INC. reported $1.40B in revenue while BIOGEN INC. reported $9.89B.
Full pages: HALOZYME THERAPEUTICS, INC. and BIOGEN INC., or browse the full rankings.